Rare cytogenetic abnormalities and alteration of microRNAs in acute myeloid leukemia and response to therapy

  • Mohammad Shahjahani Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Elham Khodadi Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Mohammad Seghatoleslami Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Javad Mohammadi Asl Department of Medical Genetics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Neda Golchin Noor Clinical & Specialty Laboratory, Ahvaz, Iran, Islamic Republic of.
  • Zeynab Deris Zaieri Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Najmaldin Saki | najmaldinsaki@gmail.com Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.

Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, which is heterogeneous in terms of morphological, cytogenetic and clinical features. Cytogenetic abnormalities, including karyotype aberrations, gene mutations and gene expression abnormalities are the most important diagnostic tools in diagnosis, classification and prognosis in acute myeloid leukemias. Based on World Health Organization (WHO) classification, acute myeloid leukemias can be divided to four groups. Due to the heterogeneous nature of AML and since most therapeutic protocols in AML are based on genetic alterations, gathering further information in the field of rare disorders as well as common cytogenetic abnormalities would be helpful in determining the prognosis and treatment in this group of diseases. Recently, the role of microRNAs (miRNAs) in both normal hematopoiesis and myeloid leukemic cell differentiation in myeloid lineage has been specified. miRNAs can be used instead of genes for AML diagnosis and classification in the future, and can also play a decisive role in the evaluation of relapse as well as response to treatment in the patients. Therefore, their use in clinical trials can affect treatment protocols and play a role in therapeutic strategies for these patients. In this review, we have examined rare cytogenetic abnormalities in different groups of acute myeloid leukemias according to WHO classification, and the role of miRNA expression in classification, diagnosis and response to treatment of these disorders has also been dealt with.

Downloads

Download data is not yet available.
Published
2015-03-09
Section
Reviews
Keywords:
rare abnormalities, microRNAs, therapy, acute myeloid leukemia.
Statistics
Abstract views: 2563

PDF: 1050
HTML: 1026
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Shahjahani, M., Khodadi, E., Seghatoleslami, M., Mohammadi Asl, J., Golchin, N., Zaieri, Z., & Saki, N. (2015). Rare cytogenetic abnormalities and alteration of microRNAs in acute myeloid leukemia and response to therapy. Oncology Reviews, 9(1). https://doi.org/10.4081/oncol.2015.261

Most read articles by the same author(s)